GlaxoSmithKline is exploring how to integrate Apple’s ResearchKit into its clinical trials, setting it up to be one of the first drug developers to adopt the recently introduced platform.
But as many have already found out, using mobile technology can throw up a number of patient privacy and data confidentiality issues that a company needs to resolve before incorporating Apple’s tool into their research programs. For some, the potential benefits don’t yet outweigh the costs. Gilead and Pfizer both said they have no plans to use ResearchKit. Find out more here.
Find out more on how to validate mobile apps to pharmaceutical industry standards here.